Tislelizumab: First Approval, PMID: 32185681
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC), PMID: 33044117
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma, PMID: 32561664
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study, PMID: 31520078
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study, PMID: 32561638
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors, PMID: 32540858
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma, PMID: 33047430
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma, PMID: 30969136
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial, PMID: 31378459
A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients, PMID: 32769013
Tislelizumab for the treatment of classical Hodgkin's lymphoma, PMID: 33332484
Antibodies to watch in 2019, PMID: 30516432
Nivolumab for the treatment of hepatocellular carcinoma, PMID: 30304963
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma, PMID: 33043992
Immuno-oncology for esophageal cancer, PMID: 32777942
Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study, PMID: 32690666
Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy, PMID: 32446372
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances, PMID: 30380773
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies, PMID: 31362369
Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage, PMID: 33527708
Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis, PMID: 32239681
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial, PMID: 33792623
Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer, PMID: 31808542
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial, PMID: 34033975
Tislelizumab-A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer, PMID: 33792622
Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report, PMID: 34459463
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma, PMID: 34269067
Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma, PMID: 33868256
Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide, PMID: 34322131
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer, PMID: 33866751
Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection, PMID: 33869071
Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report, PMID: 34368325
Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report, PMID: 33656285
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response, PMID: 33334744
Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient, PMID: 34040602
Successful treatment of two patients with unresectable lung squamous cell carcinoma with tislelizumab regardless of programmed death-ligand 1 expression: a report of two cases, PMID: 34459453
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research, PMID: 31475974
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population, PMID: 32968172
Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency, PMID: 32442647
Association of Hypoactive and Hyperactive Delirium With Cognitive Function After Critical Illness, PMID: 32317589
Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268], PMID: 34127281
Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond, PMID: 33602008
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma, PMID: 33224963
Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317, PMID: 32172642
Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T/NK Cell Lymphoma: A Case Report, PMID: 34277451
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD, PMID: 33868266
Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma, PMID: 33732355
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives, PMID: 34305619
Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer, PMID: 34095230
Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature, PMID: 34044548
The Synergistic and Attenuated Mechanism of Action of the Xihuang Pill in Dual Immunotherapy After Stenting for Advanced Cholangiocarcinoma: A Controlled Clinical Trial., PMID:40529349
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study., PMID:40528576
Renal-Limited Thrombotic Microangiopathy Induced by Fruquintinib and Tislelizumab: A Case Report., PMID:40528285
Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study., PMID:40526208
Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study., PMID:40521010
Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China., PMID:40520302
Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient., PMID:40519910
Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series., PMID:40496871
Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma., PMID:40495894
Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system., PMID:40491908
A rare case of rectal malignant melanoma with long-term survival: case report and literature review., PMID:40483466
Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma., PMID:40474969
Combined effect of Tislelizumab and chemotherapy on tumor control rate and prognosis in patients with small cell lung cancer., PMID:40469132
Guidelines of Onkopedia: What is new? Esophageal Cancer., PMID:40451170
PD-1 monoclonal antibody (Tislelizumab)-induced DRESS syndrome in an intrahepatic cholangiocarcinoma patient with FGFR3 mutation and elevated IgG4:A case report., PMID:40447060
Primary adenocarcinoma of the renal pelvis: A case report., PMID:40441222
A case of diabetic ketoacidosis triggered by immune checkpoint inhibitors in the treatment of recurrent nasopharyngeal carcinoma., PMID:40439560
Rechallenge of anti-PD-1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report., PMID:40438874
Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab: A case report., PMID:40420929
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial., PMID:40414961
Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial., PMID:40414848
Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial., PMID:40413023
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer., PMID:40411966
[Short-term effects and safety outcomes of the combination of tislelizumab and neoadjuvant chemotherapy in the perioperative treatment of locally advanced gastric cancer]., PMID:40404373
Neoadjuvant arterial infusion chemotherapy combined with immunotherapy in treating locally advanced lower esophageal and esophagogastric junction cancer., PMID:40400978
Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma., PMID:40397297
Insights into Sorafenib resistance in hepatocellular carcinoma: Mechanisms and therapeutic aspects., PMID:40389183
Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial., PMID:40382318
Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report., PMID:40375998
[Analysis of the efficacy of neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer patients after percutaneous coronary intervention]., PMID:40374341
Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab., PMID:40373876
Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867
Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study., PMID:40356893
A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment., PMID:40350385
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia., PMID:40313949
SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review., PMID:40313929
Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review., PMID:40313419
Unexpected outcomes of tislelizumab treatment in thoracic metastasis of malignant phyllodes tumors: a case report and literature review., PMID:40297816
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact., PMID:40286322
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model-Based Approach., PMID:40286320
Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study., PMID:40268516
Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis., PMID:40264761
Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma., PMID:40257370
Pulmonary artery pseudoaneurysm-induced massive hemoptysis after chemotherapy combined with tislelizumab for lung squamous cell carcinoma: a case report., PMID:40248079
Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis., PMID:40247711
Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study., PMID:40240993
Efficacy of Tislelizumab in Lung Cancer Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:40230743
Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First-Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study., PMID:40228531
Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report., PMID:40226819
For research use only. Not for human or drug use.
